16 April 2014 - Hepatitis C patients in the UK are celebrating the news that NHS England has approved an £18.7 million investment to pay for Gilead Science's controversial treatment Sovaldi.

Around 500 patients with acute liver failure, and/or awaiting liver transplantation, are expected to benefit from the decision to fund Sovaldi (sofosbuvir), taken by NHS England’s Clinical Priorities Advisory Group. Until the National Institute for Health and Care Excellence completes its review later this year, the move means that the drug will be funded for those patients at significant risk of mortality or who require transplantation.

For more details, go to: http://www.pharmatimes.com/Article/14-04-16/NHS_England_to_fund_hepatitis_C_drug_Sovaldi.aspx#ixzz2zC0w4DkW